Astellas has signed an exclusive option and license agreement with Audax Biosciences for DAX-044, an experimental cancer immunotherapy designed to concentrate immune stimulation within the tumor microenvironment. The agreement reflects continued interest in interleukin-12 (IL-12), despite the toxicity problems that have complicated its development for decades. (Fierce Biotech’s coverage of the Astellas–Audax agreement)
| Item | Details |
|---|---|
| Company | Audax Biosciences / Astellas |
| Candidate | DAX-044 |
| Modality | Immune-targeted IL-12 antibody–cytokine fusion |
| Platform | AVIKINE |
| Intended use | Cancer immunotherapy for solid tumors |
| Development stage | Preclinical; studies supporting clinical trial applications are underway |
| Agreement | Exclusive option to obtain a worldwide development, manufacturing and commercialization license |
| Next milestone | Phase 1 trial expected to begin in 2027 |
The challenge for IL-12 has been how to harness its immune-activating effects without causing excessive toxicity throughout the body. DAX-044 attempts to address that problem through molecular engineering, aiming to direct its activity toward the tumor microenvironment while limiting effects elsewhere.
According to Fierce Biotech, the candidate has reduced affinity for the IL-12 receptor to limit engagement with peripheral immune cells. An antigen-binding component is designed to direct DAX-044 toward certain immune cells in the tumor microenvironment, while an Fc component is intended to extend its half-life. These features aim to improve the balance between antitumor activity and systemic toxicity, but their performance in patients remains unproven.
The agreement leaves Audax responsible for funding and advancing DAX-044 into Phase 1. Astellas would assume responsibility for worldwide development, manufacturing and commercialization if it exercises its option. Audax retains an option to co-fund and co-promote the candidate in Australia and New Zealand.
The financial terms include a combined $285 million in upfront and potential option-exercise payments, plus up to $1.05 billion in development and commercial milestones. Audax could also receive tiered double-digit royalties on worldwide net sales if DAX-044 is approved. The upfront payment has not been separately disclosed; the combined figure should not be interpreted as cash paid in full at signing.
I find this approach interesting because it revisits a longstanding problem in cancer treatment: a powerful biological effect is only useful if patients can tolerate it. I welcome Astellas and Audax’s efforts to address that challenge, while recognizing how early the program remains. The first human studies should provide a clearer indication of whether this design can translate into a practical treatment option.
You can also read my latest analysis of GSK and Hansoh’s Phase 3 osteosarcoma results.
Leave a Reply